VERV
Verve Therapeutics, Inc.
12.81
USD
This page is just a preview of the data found in TrendSpider’s full version
Verve Therapeutics, Inc. stock is down -18.41% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 6 PUTs, 4 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 14 Nov 16:32 | 17 Nov, 2023 | 12.50 | 2300 | ||
| 14 Nov 16:39 | 17 Nov, 2023 | 17.50 | 307 | ||
| 14 Nov 20:26 | 17 Nov, 2023 | 12.50 | 2300 | ||
| 15 Nov 16:17 | 17 Nov, 2023 | 10.00 | 1610 | ||
| 16 Nov 15:32 | 17 Nov, 2023 | 10.00 | 1180 | ||
| 16 Nov 15:35 | 17 Nov, 2023 | 15.00 | 2519 | ||
| 16 Nov 15:39 | 17 May, 2024 | 10.00 | 165 | ||
| 17 Nov 18:24 | 17 Nov, 2023 | 15.00 | 2010 | ||
| 17 Nov 20:09 | 17 Nov, 2023 | 10.00 | 1177 | ||
| 05 Dec 17:09 | 17 May, 2024 | 7.50 | 96 |
Verve Therapeutics, Inc. engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
